Our mission is to enable access to high quality, affordable,
specialty NGS testing, performed by any NGS laboratory as
clinical grade tests, closer to home, for all patients.

Leadership Team

Randy Pritchard

Chief Executive Officer Mr. Randy Pritchard is CEO of Pillar Biosciences. He has more than 24 years of healthcare experience as a diagnostics executive who has deep experience in corporate and commercial strategy, sales and marketing, and driving growth through innovation. He has held positions of increasing responsibilities, including SVP of US Diagnostics marketing, SVP & Lifecycle Leader at the divisions of POC Diagnostic & Core Reagents, and VP of Marketing at Centralized Diagnostics at Roche Diagnostics. He completed his undergraduate studies at Purdue University and his MBA at Indiana Wesleyan University.

Zhaohui Wang, Ph.D.

Co-founder and Chief Scientific Officer Dr. Zhaohui Wang co-founded Pillar Biosciences, and co-invented SLIMamp technology. Previously, she held positions of increasing responsibility at LabCorp (previously Genzyme Genetics) and IQuum (subsequently acquired by Roche Molecular Diagnostics). Dr. Wang received her Ph.D. in Cellular and Molecular Biology from the University of Massachusetts, Amherst.

Rich Shea Headshot

Rick Shea

Chief Financial Officer Rick Shea served as the Chief Financial Officer of Syndax Pharmaceuticals, Inc. from February 2017 to July 2020. Rick previously served as a member of the Syndax Pharmaceuticals board of directors from January 2014 to February 2017. From July 2007 through December 2016, he served as Senior Vice President and Chief Financial Officer of Momenta Pharmaceuticals Inc., a publicly traded biotechnology company, and was its Vice President and Chief Financial Officer since October 2003. Prior to joining Momenta, Rick served as Chief Operating Officer and Chief Financial Officer of Variagenics Inc., a publicly traded pharmacogenomics company, that was merged with Hyseq Pharmaceuticals Inc., and as Vice President, Finance of Genetics Institute, Inc., a publicly traded biotechnology company, which was acquired by Wyeth Pharmaceuticals, Inc., which was then acquired by Pfizer, Inc. Rick received an AB from Princeton University and an MBA from the Public Management Program at Boston University.

Laura Beggrow

Laura Beggrow

Chief Business Officer Laura possesses close to 30 years of leadership experience in the molecular diagnostics, biotechnology and pharmaceutical industries. Most recently, Ms. Beggrow served as President of Molecular Diagnostics at HTG Molecular. Prior to this, Laura was the Chief Commercial Officer at Celcuity where she led early corporate strategic planning and clinical pipeline development for three years. She began her molecular diagnostic career in 2004 at Genomic Health serving as VP of Sales & Marketing and leading the commercial organization for close to nine years. Prior to Genomic Health, she served in a variety of commercial leadership positions in specialty therapeutics (cardiovascular, neurology and oncology) with big pharma, biotech and smaller start-up organizations. Laura is an effective business leader and helped take two companies successfully public (Celcuity and Genomic Health). She holds a Bachelor of Science Degree in Nursing from The Ohio State University.

Martin Zillmann photo

Martin Zillmann, Ph.D.

Chief Operating Officer Dr. Martin Zillmann, Pillar Biosciences' Chief Operating Officer, has a long history in nucleic acid diagnostics that started with his role as Director of Assay Development at Variagenics, a pioneer in the field of personalized medicine. Most recently, he served as Head of the Technology Office for the Process Solutions business of MilliporeSigma. Dr. Zillmann holds a Ph.D. in Biochemistry from Rice University.

Board of Directors

Dr. Gang Song is the founder of Pillar Biosciences, who co-invented Pillar Biosciences’ SLIMamp® technology. He subsequently founded Affyimmune Therapeutics, a cellular immunotherapy company. Previously, Dr. Song was a Technical Lead at Integrated Genetics, LabCorp (previously Genzyme Genetics), and prior to that, was a Project Lead at IQuum before its acquisition by Roche Molecular Diagnostics. Dr. Song completed his postdoctoral training in Timothy Springer’s lab at Harvard Medical School and received his Ph.D. from Shanghai Medical College of Fudan University, China.

Mr. Randy Pritchard is CEO of Pillar Biosciences. He has more than 24 years of healthcare experience as a diagnostics executive who has deep experience in corporate and commercial strategy, sales and marketing, and driving growth through innovation. He has held positions of increasing responsibilities, including SVP of US Diagnostics marketing, SVP & Lifecycle Leader at the divisions of POC Diagnostic & Core Reagents, and VP of Marketing at Centralized Diagnostics at Roche Diagnostics. He completed his undergraduate studies at Purdue University and his MBA at Indiana Wesleyan University.

Robert Forrester has more than two decades of experience serving as chief executive officer or chief financial officer for both private and public biopharma companies. Prior to joining EQRx, Robert was CEO of Verastem Oncology, Chief Operating Officer or Chief Financial Officer at Forma Therapeutics, CombinatoRx (now ZLCS), and Coley Pharmaceutical Group. Robert also served as Managing Director of the Proprietary Investment Group at MeesPierson. He holds a LL.B. from Bristol University.

Simone Song is the founder and senior partner of ORI Capital. She serves as investor director on a number of companies that ORI Healthcare Fund has invested, including AffyImmune, Cold Genesys, Enable Injections, Kymab, Pillar Biosciences, TriSalus Medical, etc. Simone was the former Head of Goldman Sachs Healthcare Investment Banking for Greater China. Prior to joining Goldman Sachs, she was a Managing Director of Cowen Group, a member of the advisory board of AXA Investment Managers, and an executive board advisor to AXA Asia Pacific Holdings. Simone received a BA in Economics from Fudan University in China and an MA in Economics from Claremont Graduate School.

Elaine is a Director of ORI Capital. She leads the deal initiation, due diligence and execution process as well as the post investment portfolio management activities. Elaine was a Vice President of Goldman Sachs Healthcare Investment Banking for Greater China. Prior to joining Goldman Sachs, she was Assistant Manager with the Audit & Assurance Division of KPMG China. Elaine received a BA in English Literature from Tsinghua University and an MBA from UCLA Anderson School of Management. She is a licensed CPA by the Chinese Institute of Certified Public Accountants.

Dr. Zhaohui Wang co-founded Pillar Biosciences, and co-invented SLIMamp technology. Formerly, she was an Associate Vice President at Integrated Genetics in the genomics laboratory at Laboratory Corporation of America (previously Genzyme Genetics). Prior to LabCorp, Dr. Wang was a group leader at IQuum (now Roche Molecular Diagnostics). Dr. Wang received her Ph.D. in Cellular and Molecular Biology at the University of Massachusetts, Amherst and her undergraduate degree from Peking University, China.

Dr. Eric Lai has more than 20 years’ experience in drug and IVD molecular diagnostic development. Dr. Lai was SVP of Genomic Medicine at Takeda, and before that he was SVP of Research & Development at Gen-Probe (now part of Hologic) and VP of Pharmacogenetics at GlaxoSmithKline. Dr. Lai received his Ph.D. from Columbia University and did his post-doctoral training in Dr. Hood’s lab at CalTech in the early days of the Human Genome Project. Dr. Lai focused on clinical applications of Pharmacogenomics in drug development and safety. In 2002, he discovered the association of HLA5701 to Abacavir hypersensitivity. This discovery is frequently cited in FDA guidance as one of the most important demonstrations of precision medicine.

Scientific Advisory Board

Siraj Ali, MD, Ph.D.

VP of Clinical Development, EQRx Inc.

Cheng-Zhong Zhang, Ph.D.

Co-Founder, Pillar Biosciences Assistant Professor, Harvard Medical School

Marcia Eisenberg, Ph.D.

Chief Scientific Officer and Sr. VP, LabCorp

Timothy Springer, Ph.D.

Professor, Harvard Medical School

Paul M. Waring, MBBS, Ph.D., FRCPA, FRCPath, FHGSA, FFSc(RCPA)

Executive Director, Translational Pathology, AstraZeneca

Investors

WP Feedback

Dive straight into the feedback!
Login below and you can start commenting using your own user instantly

Scroll to Top